Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination
| Autor: | Poonkiat Suchonwanit, Kanchana Leerunyakul, Kallapan Pakornphadungsit |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Medicine (General) Triamcinolone acetonide coronavirus pityriasis rosea immunization R5-920 vaccine adverse effect Pandemic cutaneous eruptions case report Medicine Adverse effect Contraindication business.industry SARS-CoV-2 General Medicine medicine.disease Dermatology Vaccination Immunization Pityriasis rosea business Complication medicine.drug |
| Zdroj: | Frontiers in Medicine, Vol 8 (2021) Frontiers in Medicine |
| DOI: | 10.3389/fmed.2021.752443/full |
| Popis: | Vaccination is one of the cornerstones in the efforts towards ending the coronavirus disease 2019 (COVID-19) pandemic. However, several adverse effects of COVID-19 vaccination have been identified. Pityriasis rosea (PR)-like eruption is a rare cutaneous complication of immunization. To the best of our knowledge, there have been no reports of PR-like eruptions following inoculation with Oxford/AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine. Here, we described a case of PR-like eruption that developed 14 days after Oxford/AstraZeneca vaccination in a 52-year-old Thai woman with glioblastoma. Treatment with topical 0.1% triamcinolone acetonide twice per day showed partial response after seven days. Despite this rare complication, our report highlights that the presence of PR-like eruption is not a contraindication for subsequent vaccinations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|